Vaxxinity to Present at the 39th Annual J.P. Morgan Healthcare Conference

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39^th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST. Vaxxinity will result from the combination between C19 Corp. (d/b/a COVAXX) and United Neuroscience, Ltd. expected to close in the coming weeks.

Vaxxinity is being formed to pioneer the development and deployment of a new class of synthetic peptide vaccines to democratize the treatment of chronic diseases as well as COVID-19 and derivative viruses.

Mei Mei Hu, Co-Founder and Chief Executive Officer, will provide an overview of the combined company, its vaccine platform technology and its drug pipeline, as well as its upcoming milestones during a webcast at the 39^th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST.

A live audio webcast of the presentation may be accessed for up to 30 days after the event here: https://jpmorgan.metameetings.net/events/healthcare21/sessions/36546-vaxxinity/webcast?gpu_only=true&kiosk=true

About Vaxxinity

Vaxxinity, Inc. is a to-be-formed U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Vaxxinity will result from the combination between C19 Corp. (d/b/a COVAXX) and United Neuroscience, Ltd. expected to close in the coming weeks. Headquartered in Hauppauge, New York, and with combined operations around the World, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and neurodegenerative diseases, including Alzheimer's, Parkinson’s diseases and chronic traumatic encephalopathy. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health with a high probability of success. The key to the platform is the proprietary library of UBITh immunogens, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.

COVAXX’s COVID-19 vaccine has completed Phase-1 and is entering Phase-2/3 in Taiwan, Brazil and India in Q1 and Q2 of 2021. This is one of the vaccines that will become part of Vaxxinity’s portfolio.

Vaxxinity believes that democratizing health has no limitations and no national boundaries. With a highly-respected, highly-educated and diverse team of experts, Vaxxinity has the dedication to produce the safest and most effective immunotherapeutics and vaccines and the entrepreneurial spirit to pursue innovation and scientific discovery at the highest levels to find solutions to the greatest challenges.

Forward-looking statements

The forward-looking statements made in this release relate only to the events or information as of the date on which the statements are made. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this release completely and with the understanding that our actual future results or performance, including our combination, may be materially different from what we expect. In this release, statements of, or references to, our intentions are made as of the date of this release. Any of these intentions may change in light of future developments.

Diane Murphy, COVAXX PR
+1 (310) 658.8756; diane@covaxx.com

David Schull, Russo Partners
+1 (212) 845.4271; david.schull@russopartnersllc.com